One of the bellwethers of stem cell new drug development, UnicoCell, has announced good news again that it’s stem cell drug, ELIXCYTE®, is now under phase 3 clinical trial and the mechanism has been approved and published in the Current Issue of Molecular Biology. They proved the efficacy of ELIXCYTE® in relieving joint inflammation and protecting cartilage damage.
According to the results of phase 2, not only notable anti-inflammatory and pain relief of knee OA, but the function of the knees has also been restored significantly by injections of ELIXCYTE®. Furthermore, the therapeutic effect has been followed up to one year. UnicoCell and the collaborated medical centers have completed the study of anti-inflammatory and chondroprotective mechanisms of ELIXCYTE®. The result has been published in the Current Issue of Molecular Biology on 2024.08.02; The title of the article is “ELIXCYTE®, an Allogenic Adipose-Derived Stem Cell Product, Mitigates Osteoarthritis by Reducing Inflammation and Preventing Cartilage Degradation In Vitro.
Phase 3 clinical trial for Knee Osteoarthritis has been approved to proceed by both the United States Food and Drug Administration (FDA) and the Taiwan Food and Drug Administration (TFDA). The clinical sites include Linkou Chang Gung Memorial Hospital, National Taiwan University Hospital, and Taipei Veterans General Hospital. UnicoCell is looking forward to getting the new drug approval and providing a better choice of treatments for patients in the future. Another therapeutic application on chronic kidney disease has been completed for the phase 1/2 clinical trial this year. The research progress in osteoarthritis and chronic kidney disease of UnicoCell is ahead of the world's competitors, which makes UnicoCell remain in the leading position in stem cell drug development in the industry.
Contact: Eileen Chen
Phone: 886-2-27922699
Mail: info@unicocell.com